Immune-mediated syndromes following intravenous bisphosphonate therapy

Further Publications Immunology

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?

Ann Rheum Dis.

Baker KF, Isaacs JD

doi: 10.1136/

Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma

AIDS Res Ther.

Volkow P, Cesarman-Maus G, Garciadiego-Fossas P, Rojas-Marin E, Cornejo-Juárez P

doi: 10.1186/s12981-017-0156-9.

Further Publications Immunology

Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation

J Clin Immunol

Kayaoglu B, Kasap N, Yilmaz NS, Charbonnier LM, Geckin B, Akcay A, Eltan SB, Ozturk G, Ozen A, Karakoc-Aydiner E, Chatila TA, Gursel M, Baris S

doi: 10.1007/s10875-020-00943-y

Melanoma and Skin Cancer

Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis

JAMA Dermatol

Durgin JS, Jariwala NN, Wysocka M, Zhang KK, Maity A, Benoit B, Plastaras JP, Lewis DJ, Rosenthal JM, Teague JE, Berg S, Del Guzzo C, Kim EJ, Vittorio C, Haun PL, Samimi SS, Villasenor-Park J, Inverso J, Clark RA, Rook AH

doi: 10.1001/jamadermatol.2020.3958

Immunotherapy

Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome

Pediatr Neurol.

Pranzatelli MR, Tate ED

doi: 10.1016/

Autoimmune Disease

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders

Front Immunol.

Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, Crowley C, Boyman O

doi: 10.3389/fimmu.2019.01990.

Osteoporosis

Fracture risk following intermission of osteoporosis therapy

Osteoporos Int.

Dennison EM, Cooper C, Kanis JA, Bruyère O, Silverman S, McCloskey E, Abrahamsen B, Prieto-Alhambra D, Ferrari S, IOF Epidemiology/Quality of Life Working Group.

doi: 10.1007/s00198-019-05002-w.

Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis

JAMA Dermatol.

Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, Mockenhaupt M

doi: 10.1001/

Further Publications Immunology

Immune-Related Adverse Drug Reactions and Immunologically Mediated Drug Hypersensitivity

Immunol Allergy Clin North Am

Macy E

doi: 10.1016/j.iac.2020.06.003

Related content

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?

Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma

Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation

Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis

Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders

Fracture risk following intermission of osteoporosis therapy

Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis

Immune-Related Adverse Drug Reactions and Immunologically Mediated Drug Hypersensitivity